DONAUISAR Klinikum Deggendorf-Dingolfing-Landau gKU
- Address
- lock Available on a paid plan
Oncology and Breast Cancer Research
At DONAUISAR Klinikum Deggendorf-Dingolfing-Landau gKU, a major focus is neoplasms, especially studies in breast cancer and other solid tumors. The trials are exploring new and improved treatments to reduce recurrence, extend disease-free survival, and strengthen long-term cancer control.
- ER+/HER2- early breast cancer and HER2-negative breast cancer
- Triple-negative breast cancer and primary HER2-negative breast cancer
- Testing adjuvant and maintenance therapies to prevent recurrence
Research here also includes treatment strategies for ovarian cancer and broader oncology care, with the goal of improving outcomes after surgery and standard therapy.
Gastrointestinal Cancer Studies
The site is active in digestive system diseases, with trials centered on colon cancer, rectal cancer, gastric cancer, and pancreatic cancer. These studies are designed to refine treatment choices and evaluate whether additional therapy can improve survival after surgery or in advanced disease.
- Colon cancer stage II and metastatic colorectal cancer
- Resectable pancreatic ductal adenocarcinoma
- Advanced stomach and gastroesophageal junction adenocarcinoma
Several projects examine whether chemotherapy or biomarker-guided treatment can improve disease-free survival and overall survival in patients with gastrointestinal cancers.
Hematology and Blood Cancer Trials
Another important area is hemic and lymphatic diseases, including studies in chronic lymphocytic leukemia, mantle cell lymphoma, and multiple myeloma. The research is focused on improving response rates, delaying progression, and tailoring therapy for patients with higher-risk disease.
- Treatment-naïve and relapsed/refractory chronic lymphocytic leukemia
- High-risk chronic lymphocytic leukemia
- Generalized mantle cell lymphoma and multiple myeloma
These trials are evaluating new combinations and maintenance approaches to strengthen progression-free survival and deepen treatment responses.
Supportive Care and Treatment Side Effects
The research portfolio also includes nervous system diseases and supportive care studies, particularly for chemotherapy-induced polyneuropathy. This work aims to lessen treatment-related nerve damage and improve quality of life for people receiving cancer therapy.
- Prevention of chemotherapy-induced polyneuropathy
- Reducing symptoms linked to cancer treatment
- Improving comfort and daily functioning during therapy
These studies reflect a broader effort at the hospital to make cancer treatment more tolerable while preserving effectiveness.
Immune, Cardiovascular, and Other Specialized Areas
Beyond oncology, the site contributes to research in immune system diseases, cardiovascular diseases, and female urogenital diseases and pregnancy complications. While cancer remains the main emphasis, these additional fields show a broad clinical research profile across several important therapeutic areas.
- Evaluating targeted treatments in immune-related and blood cancers
- Exploring better care pathways for complex adult diseases
- Supporting treatment decisions in diverse clinical conditions
Overall, the studies at this research site are aimed at testing new therapies, improving standard care, and identifying which patients are most likely to benefit from specific treatment strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 45 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 44 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in DONAUISAR Klinikum Deggendorf-Dingolfing-Landau gKU
lock Showing 1 of 18 trials — the rest is available on a paid plan.
IMP list
lock Showing 1 of 45 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 5 | Unknown | 2019-12-04 | 2025-04-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.